BioMarin Pharmaceuticals BMRN Accrued Manufacturing Costs
Accrued Manufacturing Costs at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's accrued manufacturing costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's accrued manufacturing costs?
- BioMarin Pharmaceuticals (BMRN) reported accrued manufacturing costs of $152.61M in Q1 2026.
- How has BioMarin Pharmaceuticals's accrued manufacturing costs changed year-over-year?
- BioMarin Pharmaceuticals's accrued manufacturing costs increased by 17.2% year-over-year, from $130.23M to $152.61M.
- What is the long-term trend for BioMarin Pharmaceuticals's accrued manufacturing costs?
- Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's accrued manufacturing costs has grown at a 5.9% compound annual growth rate (CAGR), from $165.02M to $219.42M.